SRH Commodities: Measuring Prices, Availability & Affordability (Methodology & Data Entry Manual)

SRH Commodities Methodology & Data Entry Manual | 10 October, 2017 | Download PDF

Good sexual and reproductive health (SRH) is a state of complete physical, mental and social well-being in all matters relating to reproduction for both men and women, including adolescents. Maintaining good SRH means people need access to accurate information and to safe,

Recommendations to Strengthen WHO EURO Member State Collaboration on Improving Access to Medicines

13 September, 2017 | Joint Intervention* | Download PDF

Oral Contribution: Provisional agenda item 5(d) Strengthening Member State collaboration on improving access to medicines in the WHO European Region  EUR/RC67/11 + EUR/RC67/Conf.Doc./9

Mr/Ms Chairperson,

Health Action International (HAI) and endorsing organisations welcome the opportunity to address this meeting.

Pharmaceutical Promotion in Medical and Pharmacy Education in The Netherlands: Readiness for Curriculum Change

Report | 5 July, 2017 | Download PDF

Introduction: Despite the importance of the pharmaceutical industry, a substantial amount of pharmaceutical companies’ expenditure is targeted at the promotion of pharmaceuticals in order to increase sales. This so-called pharmaceutical promotion affects, among other things, the quality, frequency and costs of prescribing, as well as the sustainability of healthcare systems,

Scenario 6: Sustainable Europe for Its Citizens

Joint Policy Brief | 20 June, 2017 | Download PDF

Health Action International is one of 250 non-government organisations from across Europe that have released an alternative vision for a more democratic, just and sustainable Europe. Intended to influence the debate on the future direction of Europe, this alternative vision is endorsed by organisations representing a multitude of public interest issues,

HAI & Global Snakebite Initiative Applaud WHO’s Adoption of Snakebite Envenoming as Top-level Neglected Tropical Disease

Press Release | 12 June, 2017 | Download PDF

Category A’ status to spark large-scale WHO action to prevent and treat catastrophic snakebite envenoming which kills and injures world’s poorest

AMSTERDAM—Health Action International (HAI) and the Global Snakebite Initiative (GSI) have commended the World Health Organization’s (WHO) landmark decision to adopt snakebite envenoming as a ‘category A’ neglected tropical disease (NTD)—the WHO’s highest possible ranking for an NTD.

Media Release: Health Action International Commend Decision By World Health Organization Not To Include Long-Acting Analogue Insulins On The Essential Medicines List

Press Release | 6 June, 2017 | Download PDF

Its inclusion would have increased pressure on national governments to purchase long-acting analogue insulins, which are seven to nine times more expensive than human insulin, while providing limited added value to users.

AMSTERDAM— Researchers conducting a global study into insulin access barriers today commended the decision made by the World Health Organization’s (WHO) Expert Committee on the Selection and Use of Essential Medicines (the ‘Expert Committee’) not to include long-acting analogue insulins on the WHO Model List of Essential Medicines (EML).

European Union Leadership Critical for Affordable & Responsible Antibiotic R&D

Policy Report | 23 May, 2017 | Download PDF

Antimicrobial resistance (AMR) is a global threat, which refers to microbes becoming resistant to antimicrobial medicines developed to treat them. Every time an antibiotic medicine is used, it increases the possibility of the microbe becoming resistant. Currently, AMR causes an estimated 25,000 deaths per year in the European Union (EU) and 700,000 worldwide.

Response to Health Canada on Release of Clinical Data

Joint Letter | 19 May, 2017 | Download PDF

May 19, 2017
Office of Information Management Resource Management and Operations
Directorate Health Products and Food Branch
Health Canada
Graham Spry Building
250 Lanark Avenue
Ottawa, Ontario, Canada
K1A 0K9

Thank you for the opportunity to comment on the Health Canada white paper entitled “Public release of clinical information in drug submissions and medical device applications”.1 Health Canada’s proposed policy change could be a major step towards transparency.

Proposed Changes to EMA’s Access to Documents Policy Fall Short on Proactive Disclosure

Press Release | 18 May, 2017 | Download PDF

BRUSSELS—The European Medicines Agency’s (EMA) proposed amendments to its access to documents policy do not sufficiently ensure comprehensive access to documents, say medicines policy watchdog organisations, Health Action International, the International Society of Drug Bulletins, NoGracias, the Nordic Cochrane Centre and Prescrire.